{"filing":{"accession_number":"0001438533-26-000046","cik":"0001438533","ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"tvtx-20260519.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000046/tvtx-20260519.htm"},"events":[{"id":9507,"run_id":8338,"accession_number":"0001438533-26-000046","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Travere Therapeutics held its Annual Meeting of Stockholders on May 19, 2026, with shareholders voting on five proposals: election of ten directors, approval of an amendment to the 2018 Equity Incentive Plan increasing authorized shares by 3,000,000, advisory approval of named executive officer compensation, advisory frequency vote on executive compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. All five proposals passed with substantial majorities.","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1163,"accession_number":"0001438533-26-000046","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2018 Equity Incentive Plan increasing authorized shares by 3,000,000 shares. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves approval of a material equity plan amendment that affects the pool of shares available for executive and employee compensation grants. While shareholder vote results are also mentioned, the substantive focus is on the equity plan amendment itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:00:46.391969+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1164,"accession_number":"0001438533-26-000046","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder voting results from Travere Therapeutics' May 19, 2026 Annual Meeting. The filing presents final voting tallies for five proposals: election of ten directors, approval of the 2018 Equity Incentive Plan amendment, advisory approval of named executive officer compensation, advisory frequency vote on executive compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material shareholder governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:00:46.391969+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1163,"accession_number":"0001438533-26-000046","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2018 Equity Incentive Plan increasing authorized shares by 3,000,000 shares. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves approval of a material equity plan amendment that affects the pool of shares available for executive and employee compensation grants. While shareholder vote results are also mentioned, the substantive focus is on the equity plan amendment itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:00:46.391969+00:00","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-05-21"},{"id":1164,"accession_number":"0001438533-26-000046","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear Item 5.07 disclosure of shareholder voting results from Travere Therapeutics' May 19, 2026 Annual Meeting. The filing presents final voting tallies for five proposals: election of ten directors, approval of the 2018 Equity Incentive Plan amendment, advisory approval of named executive officer compensation, advisory frequency vote on executive compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material shareholder governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:00:46.391969+00:00","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-05-21"}]}